Wednesday’s Midday Stock Update: Orexigen (OREX), Acura Pharmaceuticals (ACUR), ImmunoCellular Therapeutics (IMUC), Lexicon Pharmaceuticals (LXRX), Synthetic Biologics Inc (SYN)

By Carrie Williams

So far Wednesday, January 23, NASDAQ is down -3.99% and the S&P is down -3.14%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Orexigen (OREXResearch Report), Acura Pharmaceuticals (ACURResearch Report), ImmunoCellular Therapeutics (IMUCResearch Report), Lexicon Pharmaceuticals (LXRXResearch Report) and Synthetic Biologics Inc (SYNResearch Report).

Orexigen is up 185.71% in midday trading to $0.01. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00. Over the last 3 months, the insider sentiment on Orexigen has been negative based on 3 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Acura Pharmaceuticals is down -14.73% in midday trading to $0.13. Shares opened today at $0.15. The company has a 52-week low of $0.06 and a 52-week high of $0.00.

ImmunoCellular Therapeutics is up 14% in midday trading to $0.03. Shares opened today at $0.03. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

Lexicon Pharmaceuticals is down -12.61% in midday trading to $5.06. Shares opened today at $5.79. The company has a 52-week low of $5.05 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $23.67, marking a 308.81% potential upside from current levels. In a report released yesterday, Wedbush analyst Liana Moussatos maintained a Buy rating on LXRX, with a price target of $36, which represents a potential upside of 522% from where the stock is currently trading. Separately, on January 18, Needham’s Alan Carr maintained a Hold rating on the stock .

See today’s analyst top recommended stocks >>

Synthetic Biologics Inc is down -10.04% in midday trading to $0.62. Shares opened today at $0.69. The company has a 52-week low of $0.51 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $6.00, marking a 770.95% potential upside from current levels. In a report issued on January 3, H.C. Wainwright analyst Edward White maintained a Buy rating on SYN, with a price target of $6, which implies an upside of 771% from current levels.

Trending Stocks Based on Insider Activity >>